Tenderwize
Back to tender search

Open-house rebate agreement for tiotropium bromide inhalation solution

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 469 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tiotropiumbromid, Darreichungsform Inhalationslösung, ATC R03BB04

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

52 / 100

Complexity

58 / 100

Risk factors

Submission is only valid if the buyer receives the signed originals or the qualified-electronic-signature version by th...

Participation is limited to pharmaceutical companies and to medicines that are authorised and marketable in Germany.

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing tiotropium bromide, inhalation solution, ATC R03BB04.
  • Contract term up to 24 months, with earliest start on 2026-02-01 and automatic end no later than 2028-01-31.
Show full summary

This is a German open-house supply notice for non-exclusive pharmaceutical rebate agreements for tiotropium bromide inhalation solution (ATC R03BB04) with AOK Rheinland-Pfalz/Saarland. The contract window runs from 2026-02-01 to 2028-01-31, with monthly entry possible during the period. No contract value is stated. Submission is by signed paper originals or by email with qualified electronic signature; electronic submission is otherwise not allowed. The notice explicitly excludes pediatric medicines on the BfArM list and limits participation to pharmaceutical companies.

Risks

Submission is only valid if the buyer receives the signed originals or the qualified-electronic-signature version by th...

Participation is limited to pharmaceutical companies and to medicines that are authorised and marketable in Germany.

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Medicines must be approved and marketable in Germany.
  • If the medicine is already listed in Lauer-Taxe as marketable, that is treated as proof.

Eligibility

  • Only pharmaceutical companies are eligible to become contract partners.

Buyer

Lots (1)

LOT-0001

Open-house rebate agreement for tiotropium bromide inhalation solution

Single lot open-house model for non-exclusive rebate agreements covering medicines with active substance tiotropium bromide, dosage form inhalation solution, ATC R03BB04. The buyer states that all interested pharmaceutical companies may join on equal terms, without selection or individual negotiation. Pediatric medicines listed by BfArM under § 35 Abs. 5a SGB V are excluded. Contract duration is up to 24 months, starting no earlier than 2026-02-01, with monthly entry possible during the term. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Jan 2026 - Jan 2028

Category

Pharmaceutical products

Deadline

Deadline Nov 30, 2027

Procurement Details

Publication date
09 Dec 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
818511-2025

Documents (1)

Similar tenders